RxDoctor Payments DataLook up a doctor →

James Thomas, MD

Hematology & Oncology · Owensboro, KYNPI 1578566410

Payments from drug & device makers

$24,582in general payments, 2019–2025

Across 516 payments — averaging $47.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$16K
  • Novartis$870
  • Pfizer$604
  • Daiichi Sankyo Inc.$558
  • Johnson & Johnson$495
  • Gilead$494
  • plus $6K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)27$15,781
Novartis62$870
Pfizer38$604
Daiichi Sankyo Inc.26$558
Johnson & Johnson27$495
Gilead(2 entities)24$494
E.r. Squibb & Sons, L.L.C.24$411
Amgen20$395
Genentech USA, Inc.21$340
Astellas Pharma US Inc22$340
Incyte Corporation11$281
Bristol Myers Squibb16$280
Myriad Genetic Laboratories, Inc.5$249
Eisai Inc.12$208
Regeneron Healthcare Solutions, Inc.10$181
Seagen Inc.9$156
AbbVie8$148
Sanofi8$147
Tempus AI, Inc5$142
Rigel Pharmaceuticals, Inc.9$141
Takeda Pharmaceuticals U.S.A., Inc.7$134
GSK7$130
Clovis Oncology, Inc.8$126
Merck7$114
AVEO Pharmaceuticals, Inc.6$111
Mirati Therapeutics, Inc.5$101
ADC Therapeutics America, Inc.6$98
Ipsen Biopharmaceuticals, Inc5$94
Beigene USA, Inc.6$92
Puma Biotechnology, Inc.6$87
Pharmacyclics LLC, An Abbvie Company6$84
Coherus Oncology, Inc.4$81
Pharmaessentia USA Corporation4$81
Kyowa Kirin, Inc.4$72
Sumitomo Pharma America, Inc.3$69
Genmab U.S., Inc.2$59
Beone Medicines USA, Inc.3$53
Boehringer Ingelheim3$50
Iovance Biotherapeutics, Inc.4$49
Geron Corporation1$47
Tersera Therapeutics LLC3$46
Array Biopharma Inc2$45
Syndax Pharmaceuticals, Inc.2$41
Sobi, Inc2$38
AMAG Pharmaceuticals, Inc.2$32
Blue Earth Diagnostics1$29
Adaptive Biotechnologies Corporation1$29
Exelixis Inc.2$28
Pharmacosmos Therapeutics Inc.2$27
Karyopharm Therapeutics Inc.2$25
Tesaro, Inc.2$25
Progenics Pharmaceuticals, Inc.1$24
Sun Pharmaceutical Industries Inc.1$22
Celltrion USA Inc.1$22
Accord Healthcare, Inc.1$22
Sanofi-aventis U.S. LLC1$22
Ferring Pharmaceuticals Inc.1$21
Cumberland Pharmaceuticals, Inc.1$21
Fennec Pharmaceuticals, Inc.1$21
Acrotech Biopharma Inc.1$18

How this compares

$24,582 in reported general payments places this provider in the 60th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky →

Medicare billing

Part B allowed, 2024
$109,569
Medicare patients
334
Services billed
1,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Owensboro

See the full list for Kentucky →

Where these figures come from

Is this you, or does something look wrong? →